J&J, Lilly hail new data on potential diabetes drugs

Johnson & Johnson ($JNJ), Eli Lilly ($LLY) and Boehringer Ingelheim touted new late-stage data supporting their experimental diabetes drugs, part of the SGLT2 class. Another potential product in the same class, developed by AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY), was nixed by FDA early this year on safety concerns. Report